Investor relations

Investor relations

Our science-led strategy is key to delivering long-term value for patients, employees and shareholders.

NYSE: MRK
May 20, 2025 9:26 pm ET
Delayed at least 20 minutes

Latest news, events & financials

May 19, 2025

IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma

May 16, 2025

Merck to Present New Clinical and Outcomes Research Data at The American Thoracic Society’s (ATS) 2025 International Conference Demonstrating Commitment to Advancing Research in Pulmonary Arterial Hypertension

May 15, 2025

Merck Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All Comers

View all

May 27, 2025

Webcast

2025 Annual Meeting of Shareholders

Add to Calendar Webcast

June 02, 2025

Webcast

Investor Event at ASCO 2025

Add to Calendar Webcast

July 29, 2025

Earnings

Q2 2025 Earnings Call

Add to Calendar

October 30, 2025

Earnings

Q3 2025 Earnings Call

Add to Calendar

View all

1Q25 Merck Earnings Announcement
PDF

1Q25 Merck Other Financial Disclosures
PDF

View all

2025 Annual Meeting of Shareholders

Virtual-only Meeting:

We have adopted a virtual format for the 2025 Annual Meeting of Shareholders to provide a convenient and consistent experience to all shareholders regardless of location.

Add to Calendar

Webcast

See full agenda

Our pipeline shows our relentless pursuit of the next breakthrough.

Explore our pipeline

Phase II programs

80+

Phase III programs

30+

Under review

10+

Illustration of leaders speaking on stage

Our leadership

Our deep bench of talent has the knowledge, commitment and expertise to successfully execute on our innovation strategy.

Leadership

Sustainability

Supporting the future of our business and the health and well-being of patients, people and communities around the world.

Download our Impact Report 2023/2024

Download our Sustainability financing documents:

2021 Sustainability financing framework

Second-party opinion (SPO) on the bond framework

2023 Sustainability bond allocation report

2022 Sustainability bond allocation report

We're led by our science

We follow the science to our next breakthrough, leaving no stone unturned.

View our stories

Innovation

Our Q4 and full-year 2024 financial results

Merck’s (NYSE: MRK) Q4 and full-year 2024 results reflect strong growth. Our company announced Q4 worldwide sales of $15.6 billion, an increase of 7% from Q4 2023. Full-year 2024 worldwide sales were $64.2 billion, an increase of 7% from full-year 2023. “We delivered strong growth in 2024, reflecting demand for our innovative portfolio, including […]

Next: Our Q4 and full-year 2024 financial results

illustration of people building bar graph

Innovation

Our Q3 2024 financial results

Merck’s (NYSE: MRK) Q3 2024 financial results represent strong progress across the business and our diverse pipeline. Our company announced worldwide sales of $16.7 billion, an increase of 4% from Q3 2023. “Our third-quarter results were strong, as we continue to make progress heading into 2025 and beyond,” said Rob Davis, chairman and chief executive officer. […]

Next: Our Q3 2024 financial results